grant
NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade for the treatment of glioablastoma
Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 1 Jan 2025Deadline 31 Dec 2029
NIHUS FederalResearch GrantFY2025AdjuvantAdjuvant TherapyAdverse ExperienceAdverse eventAffectAfter CareAfter-TreatmentAftercareAnimal ModelAnimal Models and Related StudiesAntigen PresentationAntigen-Presenting CellsAntigensApoptosis Antigen Ligand 1AssayBioassayBiological AssayBiological MarkersBlood SampleBlood specimenBrainBrain NeoplasiaBrain NeoplasmsBrain Nervous SystemBrain TumorsCAR T cellsCAR modified T cellsCAR-TCAR-TsCD178 AntigenCD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCD95 LigandCD95 antigen ligandCNS TumorCNS neoplasmCancersCell CountCell NumberCentral Nervous System NeoplasmsCentral Nervous System TumorsCerebrospinal FluidCheckpoint inhibitorClass I AntigensClass I Major Histocompatibility AntigensClinical TrialsClinical Trials DesignComplex Class 1Correlative StudyCytometryDataDendritic CellsDoseELISPOTEncephalonExanthemExanthemaFas LigandFas-LFasL proteinFatigueFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFundingFutureGeneralized GrowthGenerationsGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGlucocorticoidsGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGranzymeGrowthHematopoietic Cell Growth FactorsHematopoietic-CGFHistocompatibility Antigens Class IHortega cellHumanHybridsIFN-GammaIFN-gIFN-γIFNGIFNγIL-7IL-7 GeneIL7IL7 ProteinIL7 geneIgDIgG4ImageImmuneImmune InterferonImmune Modulation TherapyImmune checkpoint inhibitorImmune infiltratesImmune mediated therapyImmune responseImmunesImmunoglobulin DImmunologic SubtypingImmunologically Directed TherapyImmunomodulationImmunophenotypingImmunotherapeutic agentImmunotherapyInduction TherapyInfiltrationInjection Site ReactionInjectionsInnate Immune ResponseInterferon GammaInterferon Type IIInterleukin 7 PrecursorInterleukin 7 Precursor GeneInterleukin-7Interleukin-7 GeneKO miceKeytrudaKnock-out MiceKnockout MiceLYT3LaboratoriesLack of EnergyLymphocyte CountLymphocyte NumberLymphocytic InfiltrateLymphocytopeniaLymphopeniaLymphopoietin-1MHC Class I MoleculeMHC Class I ProteinMHC class I antigenMacrophageMajor Histocompatibility Complex Class 1Malignant NeoplasmsMalignant TumorMeasuresMiceMice MammalsMicrogliaModelingModern ManMonitorMurineMusMφNEOADJNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNeuroglial NeoplasmNeuroglial TumorNull MouseOncolytic virusesOperative ProceduresOperative Surgical ProceduresPD-1 antibodyPD-1 blockadePD1 antibodyPD1 blockadePatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPerformancePeripheralPhase 1/2 Clinical TrialPhase I/II Clinical TrialRadiationRashRecombinantsRecurrenceRecurrentRegulatory T-LymphocyteReportingResearchRoleRunningSafetySamplingSkin RashSpecimen HandlingSpecimen ProcessingSurgicalSurgical InterventionsSurgical ProcedureSymptomsT cell infiltrationT cell responseT cells for CART memory cellT-CellsT-LymphocyteT8 CellsT8 LymphocytesTeff cellTemodalTemodarTestingTissue GrowthTissue SampleTotal Lymphocyte CountTransgenic MiceTreatment EfficacyTregTumor Necrosis Factor Ligand Superfamily Member 6Tumor TissueVaccinesVeiled CellsaPD-1aPD1accessory celladjuvant treatmentanti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 blockadeanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 blockadeanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyantiPD-1armbio-markersbiologic markerbioluminescence imagingbioluminescent imagingbiomarkercancer microenvironmentcell typecerebral spinal fluidcheck point blockadecheckpoint blockadechimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellscohortcommon treatmentconditional knock-outconditional knockoutcytokinecytotoxiccytotoxic CD8 T cellscytotoxic CD8 T lymphocyteeffector T cellenzyme linked immunospot assayfirst in manfirst-in-humanflow cytophotometryflugitter cellglial-derived tumorglioblastoma multiformehematopoietic growth factorhost responseimagingimmune cell infiltrateimmune check point blockadeimmune check point inhibitorimmune checkpoint blockadeimmune drugsimmune modulationimmune modulatory therapiesimmune modulatory treatmentimmune regulationimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune resistanceimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmune-modulation treatmentimmune-resistantimmuno therapyimmunogenimmunologic reactivity controlimmunologic therapeuticsimmunomodulation therapyimmunomodulation treatmentimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatoryimmunomodulatory biologicsimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulationimmunoregulatoryimmunoregulatory therapyimmunoregulatory treatmentimmunoresistanceimmunoresponseimmunotherapeuticsimmunotherapy agentimprovedimproved outcomeinduction therapiesinsightintervention efficacylFN-Gammalymphocyte pore-forming proteinmalignancymemory T lymphocytemesogliamethazolastonemicroglial cellmicrogliocytemodel of animalmouse modelmurine modelneoplasm/cancerneuroglia neoplasmneuroglia tumornew approachesnovelnovel approachesnovel strategiesnovel strategyontogenyparticipant enrollmentpatient enrollmentpatient oriented outcomespembrolizumabperforinperipheral bloodperivascular glial cellphase 2 studyphase II studypost treatmentpre-clinical studypreclinical studyregulatory T-cellsresponsesocial rolespinal fluidspongioblastoma multiformestemsuccesssurgerytemozolomidetherapeutic efficacytherapeutic immunomodulationtherapeutic immunoregulationtherapy efficacythymus derived lymphocytetraffickingtumortumor microenvironmenttumor of the central nervous systemtumors in the braintumors in the central nervous systemαPD-1αPD1
Description preview
PROJECT SUMMARY
Patients with glioblastoma (GBM) are routinely treated with radiation (RT), temozolomide (TMZ), and
glucocorticoids. However, these treatments often result in long lasting treatment-related lymphopenia
(TRL) that is associated with shorter survival. In addition, lymphopenia is associated with
unresponsiveness to checkpoint…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click